Cited by 2,471Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsPancreatic function and diabetes

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse

Open access
Hingorani, Sunil R., Petricoin, Emanuel F., Maitra, Anirban, Rajapakse, Vinodh, King, Catrina, Jacobetz, Michael A., Ross, Sally, Conrads, Thomas P. +12 more·2003·Cancer Cell

Abstract

To evaluate the role of oncogenic RAS mutations in pancreatic tumorigenesis, we directed endogenous expression of KRAS(G12D) to progenitor cells of the mouse pancreas. We find that physiological levels of Kras(G12D) induce ductal lesions that recapitulate the full spectrum of human pancreatic intraepithelial neoplasias (PanINs), putative precursors to invasive pancreatic cancer. The PanINs are highly proliferative, show evidence of histological progression, and activate signaling pathways normally quiescent in ductal epithelium, suggesting potential therapeutic and chemopreventive targets for the cognate human condition. At low frequency, these lesions also progress spontaneously to invasive and metastatic adenocarcinomas, establishing PanINs as definitive precursors to the invasive disease. Finally, mice with PanINs have an identifiable serum proteomic signature, suggesting a means of detecting the preinvasive state in patients.

Integrity signals

Registry

Crossref · 10.1016/s1535-6108(03)00309-x

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Expression of mutant Kras alone from embryonic pancreatic cells results in PanIN with histological and molecular features resembling human PDAC PanIN.

    “Expression of mutant Kras alone from embryonic pancreatic cells results in PanIN with histological and molecular features that resemble PanIN in human PDACs (72).”

    From KRAS mutation in pancreatic cancer (2021) · cites this paper as [72]

  • Conditional expression of oncogenic mutant Kras in the mouse pancreas using Cre-recombinase driven by pancreatic transcription factor promoters leads to murine PanIN lesions histologically similar to human disease.

    “conditional expression of oncogenic mutant Kras in the pancreas, using Cre-recombinase driven by pancreatic transcription factor promoters activated during embryonic development, leads to development of murine PanIN lesions histologically reminiscent of human disease28.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [28]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., Kawaguchi, Y., Johann, D., Liotta, L. A., Crawford, H. C., Putt, M. E., Jacks, T., Wright, C. V. E., Hruban, R. H., Lowy, A. M., & Tuveson, D. A.
Affiliations
  • Abramson Cancer Center (US)
  • Center for Biologics Evaluation and Research (US)
  • Johns Hopkins University (US)
  • National Cancer Institute (US)
  • Vanderbilt University (US)
  • State University of New York (US)
  • University of Pennsylvania (US)
  • Howard Hughes Medical Institute (US)
  • University of Cincinnati (US)
Corresponding author
Tuveson, David A.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2003-12
Volume
4
Issue
6
Pages
437-450
ISSN
1535-6108 (ISSN-L)
OpenAlex
W2066135299
Cited by
2,471
References
62
Citations by year
2026: 75 · 2025: 112 · 2024: 106 · 2023: 137 · 2022: 132 · 2021: 141 · 2020: 156 · 2019: 143 · 2018: 145 · 2017: 148 · 2016: 142 · 2015: 140 · 2014: 145 · 2013: 138 · 2012: 102
FWCI
18.85
Type
journal article
Language
en
Open access
Locations
  • Cancer Cell (publishedVersion)
  • PubMed (publishedVersion)
  • DigitalCommons-Cedarville (Cedarville University) (submittedVersion)
Funders
  • National Cancer Institute (R25-CA87812, P50CA-62924, R25CA087812, P50CA062924)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK050306)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
Keywords
pancreatic ductal adenocarcinoma, pancreatic intraepithelial neoplasia, KRAS G12D, oncogenic Ras mutations, pancreatic progenitor cells, pancreatic carcinogenesis, metastatic adenocarcinoma, early cancer detection, chemoprevention, mouse model
MeSH terms
Transcription Factor HES-1, Animals, Humans, Immunohistochemistry, Isoenzymes, Membrane Proteins, Mutation, Neoplasm Metastasis, Neoplasm Staging, Pancreas, Pancreatic Neoplasms, Prostaglandin-Endoperoxide Synthases, Genes, ras, Homeodomain Proteins, Matrix Metalloproteinase 7, Carcinoma, Pancreatic Ductal, Mice, Cyclooxygenase 2, Basic Helix-Loop-Helix Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review